1. Scrip
  2. >>Therapy Areas
  3. >>Alimentary/Metabolic

Pfizer Sees Once Daily Danuglipron In The “Reasonable Future”

 
• By Jessica Merrill

The obesity market offers big revenue potential but Pfizer’s oral GLP-1 candidate is currently dosed twice daily.

scale
Pfizer updated investors on its GLP-1 agonist for weight loss • Source: Shutterstock

Pfizer Inc. investors are closely watching the development of a mid-stage oral GLP-1 drug for type 2 diabetes and obesity given how lucrative the obesity market is expected to be. But if Pfizer does successfully develop danuglipron in late-stage clinical trials, the company would be entering a market dominated by experienced rivals Novo Nordisk A/S and Eli Lilly and Company.

Key Takeaways
  • Pfizer updated investors on the development of an oral GLP-1 agonist for obesity

The three companies are all working to bring oral GLP-1 drugs to market for obesity, with Novo Nordisk squarely in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

Eolo Pharma Advances In Obesity With Thermogenesis Approach

 
• By Aakash Babu

Emerging Company Profile: Early-stage biotech Eolo will seek cash and deals for its novel obesity drug SANA after positive Phase I results for weight loss, lean muscle mass preservation and fat mass reduction.

Protagonist Hopes To Come From Behind In Obesity With Oral Triple Agonist

 
• By Jessica Merrill

The company announced plans to move an oral GLP-1/GIP/GCG receptor agonist peptide into clinical development for obesity in 2026.

Altimmune’s Phase IIb MASH Data Send Share Price Plunging

 
• By Joseph Haas

Altimmune’s stock price did not recover on June 27, after a 57% dip the day before, despite efforts to position pemvidutide as both resolving MASH and offering weight loss.

Veru’s Enobosarm Market Potential Enhanced By New Obesity Data

 
• By Aakash Babu

The late-stage biotech posted results from the maintenance extension portion of its Phase IIb QUALITY trial in which enobosarm reduced weight regain and helped preserve lean mass in patients who discontinued their semaglutide weight-loss treatment.

More from Therapy Areas

Cogent Peaks With Bezaclastinib SUMMIT Results

 
• By Alaric DeArment

The biotech announced positive topline results from the Phase II SUMMIT study in non-advanced systemic mastocytosis, with data for advanced SM and GIST expected later this year.

France’s AB Science Plots Pivotal Masitinib Trial In Prostate Cancer

 
• By Kevin Grogan

Still holding out hope after multiple rejections for the tyrosine kinase inhibitor.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: AbbVie’s big autoimmune CAR-T play; In Vivo CAR-T interest grows; China deal perspectives from BIO; global pharma interest in Korea undeterred; and a look at the biggest drug sales disappointments.